Genetic Causes of Generalized Epilepsies

Ingo Helbig, MD¹,²

¹Division of Neurology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
²Department of Neuropediatrics, Christian-Albrechts-University of Kiel and University Medical Center Schleswig-Holstein (UKSH), Kiel, Germany


Abstract

Generalized epilepsies, particularly the idiopathic or genetic generalized epilepsies (GGEs), represent some of the most common epilepsies. Clinical genetic data including family studies and twin studies provide compelling evidence for a prominent genetic impact. The first decade of the 21st century was marked by progress in understanding the basic biology of generalized epilepsies including generalized/genetic epilepsies with febrile seizures plus (GEFS + ) and GGE through studies of large families, discovering causative mutations in SCN1A, SCN1B, GABRG2, and GABRA1. Subsequently, recurrent microdeletions at 15q13.3, 16p13.11, and 15q11.2 were found to be relevant risk factors for nonfamilial GGE. Genes for epileptic encephalopathies such as SLC2A1 were rediscovered in GGE, highlighting the biological continuum between different epilepsies. Genome-wide studies examining common genetic risk factors identified common variants in SCN1A, indicating a convergence of shared pathophysiological pathways in various types of epilepsies. In the era of next-generation sequencing, however, the GGEs appear more complex than expected, and small or moderately sized studies give only a limited genetic perspective. Thus, there is a strong impetus for large collaborative investigations on an international level.

The common generalized epilepsies account for up to one-third of all epilepsies, presenting one of the most common epilepsy subtypes encountered by neurologists.¹ Most patients with generalized epilepsies either present with one of three subtypes; childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), or juvenile myoclonic epilepsy (JME). These conditions, formerly referred as the idiopathic generalized epilepsies (IGEs), are characterized by an electroclinical phenotype with a combination of typical absence seizures, myoclonic seizures, and primary generalized tonic-clonic seizures. The electroencephalogram (EEG) is characterized by generalized discharges of 3 to 6 Hz or faster on an otherwise normal background. Neuroimaging, if performed, is usually normal, and patients have no or little cognitive impairment or neurodevelopmental comorbidities. For a clinician, these disorders are both straightforward and perplexing at the same time. On the one hand, a typical constellation of clinical seizure types and electrographic features allows for an accurate clinical diagnosis, and in many cases, treatment is successful with antiepileptic medication. On the other hand, the etiology of these conditions is enigmatic. The generalized discharges found in these conditions conceptually suggest that the underlying pathophysiology may be diffuse, and the frequent lack of neurodevelopmental comorbidities implies that the molecular pathways leading to seizures may be specific for paroxysmal hypersynchrony in the absence of more global clinical findings. This combination has made the primary generalized epilepsies a fascinating target for research.

Categories and Diseases

Despite their frequency and distinct clinical presentation, precise classification of the generalized epilepsies has often
presented a challenge, balancing the clarity of the electroclinical syndromes against the uncertainty of the underlying etiology. The most recent classification of the International League Against Epilepsy re instituted the concept of electroclinical syndromes, reflecting the clinical patterns of most of the generalized epilepsies. In contrast to previous classifications, the most recent classification has abandoned the terminology “idiopathic generalized epilepsy” because of the vagueness and ambiguity of the underlying concepts. However, given the frequently observed overlap of clinical features, the League suggested referring to this group of epilepsies collectively as "genetic generalized epilepsies" (GGEs), although this terminology is not uniformly accepted. For the purpose of this review, generalized epilepsies are conceptualized as a combination of the GGE proper and the generalized/genetic epilepsies with febrile seizures plus (GEFS+). The genetics of the epileptic encephalopathies— an expanding and exciting area—will not be covered in this review with the exception of rare epilepsies that largely overlap with GGE, such as early-onset absence epilepsy (EOAE) and myoclonic astatic epilepsy (MAE).

Genetic Epidemiology

There are few neurodevelopmental disorders that provide such striking evidence for a genetic cause as the electroclinical syndromes of childhood absence epilepsy, juvenile absence epilepsy, and juvenile myoclonic epilepsy. Several twin studies, starting with the classical studies by William G. Lennox in the 1940s, suggest that the concordance in identical twins exceeds 90%. This, compared with the much lower concordance in nonidentical twins, suggests that on a population level, the vast majority of causative factors are genetic. This overwhelming role of genetic factors is reflected in genetic epidemiological studies, which suggest that the recurrence in siblings for CAE, JAE, and JME is higher than in other epilepsies. For example, in a recent detailed population-based study, the standardized incidence ratio for CAE, JAE, and JME was 6.0, almost twice as high as for all epilepsy combined (standardized incidence ratio [SIR] = 3.3).

Familial Epilepsies

The dawn of gene discovery in human epilepsies was made possible by deciphering the underlying genetic defect in large autosomal dominant families with GEFS+ and GGE. The concept of GEFS+ depends upon a familial constellation of clinical symptoms, with febrile seizures as the main feature. However, in contrast to familial febrile seizures, affected individuals and/or family members have additional seizures types or epilepsy syndromes. This phenotypic constellation in families represents a spectrum, often referred to as the GEFS+ spectrum. The clinical recognition of the diverse GEFS+ phenotypes in a single family as the variable expression of a single genetic disease rather than random association of diverse phenotypes was the key step to identifying SCN1A, SCN1B, and GABRG2 as genes for monogenic epilepsies. SCN1A and SCN1B code for subunits of voltage-gated sodium channels; GABRG2 is the gene for the gamma-2 subunit of the GABA-A receptor. All three findings were pivotal in establishing the channelopathy concept of human epilepsies, postulating ion channel alterations as the main pathological correlate of human seizure disorders (Fig. 1).

The prominence of mutations in these genes in the rare syndrome of GEFS+ is in contrast to the relative paucity of gene discoveries in the common epilepsies of GGE and febrile seizures alone: This is remarkable and not easily explained. However, after discovery of these three genes, discovery of other genes for GEFS+ stagnated for more than a decade until the recent discovery of STX1B mutations in GEFS+. STX1B codes for syntaxin 1B, a critical component of the presynaptic fusion machinery. Genetic studies in large families with GGE identified mutations in GABRG2 in families with absence epilepsy as the predominant phenotype and GABRA1 in families with juvenile myoclonic epilepsy. GABRA1 encodes the α-1 subunit of the human GABA-A receptor, further adding to the prevailing channelopathy concept of human epilepsies. EFHC1 coding for the EF-hand domain-containing protein 1 was initially suggested as a gene for familial juvenile myoclonic epilepsy. However, recent studies cast doubt on whether the identified variants were in fact causative, given the enormous genetic variability of the EFHC1 gene and the frequency of apparently causative mutations in control databases. In addition, the rare variants in CACNA1H, coding for a T-type calcium channel important in the thalamocortical circuitry, may predispose to GGE. However, this finding has not yet been confirmed in the era of high-throughput sequencing, and it is currently unclear if and to what extent genetic variation in CACNA1H contributes to GGE. More recently, mutations in SLC2A1 were identified in patients with rare generalized epilepsies including frequencies of up to 10% in early-onset absence epilepsy (EOAE) and myoclonic astatic epilepsy (MAE). SLC2A1 or GLUT1 codes for the major glucose transporter in the mammalian blood–brain barrier and had previously been described in patients with severe epileptic encephalopathies and hypoglycorrhachia and patients with paroxysmal exercise-induced dyskinesia. Many patients with SLC2A1-associated generalized epilepsies have familial forms, and some rare patients with otherwise typical GGE syndromes may have SLC2A1 mutations. This finding, in combination with the ketogenic diet as a possible treatment option, may suggest screening for GLUT1 deficiency through metabolic or genetic studies in patients with difficult-to-treat GGE.

Copy Number Variations

After almost a decade of stagnation in gene discovery in the generalized epilepsies, copy number variations (CNVs) emerged as significant risk factors for the GGE. Copy number variations or structural genomic variants are small deletions or duplications of genomic material larger than 1 kb. Given that alterations of chromosomal dosage were difficult to assess using sequencing technologies, the extent of structural genomic variability had been previously underestimated. Novel technologies that could assess the amount of structural
genomic variation on a genome-wide scale, including array comparative genomic hybridization and single nucleotide polymorphism (SNP) arrays, eventually allowed for a first insight into the unexpectedly frequent type of genetic variation from 2005 onwards. Analysis of large cohorts of patients with GGE showed that 1% of all patients with GGE carried a microdeletion at 15q13.3, which was virtually absent in controls. Subsequently, microdeletions at 16p13.11 and 15q11.2 were found in GGE, as well as in single individuals with deletions at 1q21.1, 16p11.2, and 22q11.2. All these microdeletions were previously found in other neurodevelopmental disorders including autism, intellectual disability, and schizophrenia. The common theme of these alterations is their genomic mechanism. These microdeletions are recurrent, arising de novo in unrelated individuals. This phenomenon is due to flanking segmental duplications serving as default breakpoints during a process referred to as nonallelic homologous recombination (NAHR) during meiosis. Basically, given the similarity of the flanking chromosomal regions, the replication machinery introduces deletions or duplications through unequal matching of chromosomal strands. Chromosomal regions flanked by such segmental duplications are referred to as genomic hotspots. Many known genetic syndromes including Charcot–Marie–Tooth syndrome, Angelman syndrome, or Di George syndrome are largely due to structural genomic variations at such loci. Accordingly, diseases arising from genomic hotspots are referred to as genomic disorders. Given that most genomic disorders have distinct clinical features, the discovery of genomic hotspot deletions in GGE was surprising, particularly because microdeletion carriers with GGE frequently did not have comorbid neurodevelopmental disorders. Particularly, the discovery of microdeletions at 15q13.3, 16p13.11, and 15q11.2 helped to establish a novel view of the genetic architecture of GGE, emphasizing the shared genetic factors with other neurodevelopmental disorders. Collectively, it is assumed that on a population level, up to 2% to 3% of the genetic liability to GGE can be explained through these recurrent microdeletions. Although the 15q13.3 microdeletion is assumed to confirm a relatively high risk to GGE, the individual contribution of 16p13.13 and 15q11.2 microdeletions, also present in 0.5% to 1% of patients, is lower given the presence in control populations. In summary, copy number variants emerged as unexpected risk factors for generalized epilepsies, establishing the first rare genetic risk factors.

### Table 1 Genetic risk factors for the generalized epilepsies

<table>
<thead>
<tr>
<th>Autosomal dominant causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEFS+</td>
</tr>
<tr>
<td>SCN1A, SCN1B, GABRG2, STX1B</td>
</tr>
<tr>
<td>GGE</td>
</tr>
<tr>
<td>GABRG2, GABRA1, EFHC1</td>
</tr>
<tr>
<td>Rare genetic risk factors</td>
</tr>
<tr>
<td>microdeletions 15q13.3, 16p13.11, 15q11.2</td>
</tr>
<tr>
<td>CACNA1H</td>
</tr>
<tr>
<td>Common genetic risk factors</td>
</tr>
<tr>
<td>CHRM3, VRK2, ZEB2, SCN1A, PNPO</td>
</tr>
</tbody>
</table>

Abbreviations: GEFS+, generalized/genetic epilepsies with febrile seizures plus; GGE, genetic generalized epilepsies.

*aQuestionable.*

---

**Fig. 1** Gene discovery in the generalized epilepsies. Gene discovery in the generalized epilepsies can be distinguished into four different phases: (1) The initial era of linkage studies in large families, which led to the (2) era of candidate gene sequencing when gene discovery through candidate genes did not adhere to the initially assumed trajectory of identifying explanatory ion channel genes; the (3) era of genome-wide studies including copy number variation (CNV) analysis and genome-wide association studies (GWASs); and (4) the era of massive parallel sequencing, which has only just started in the generalized epilepsies.
for common epilepsies.\(^{34}\) The analysis of copy number variants presents a first foray into the detection of genetic risk factors through genome-wide studies and already foreshadowed some of the complexities with rare genetic risk factors compared with monogenic variants. For example, despite the high odds ratio (OR) of the 15q13.3 microdeletion (OR = 68), family studies frequently revealed a counterintuitive segregation pattern, characterized by an apparent lack of segregation of the variant with the familial disease phenotype.\(^{35}\)

**Genome-Wide Association Studies**

Genome-wide association studies (GWASs) query the association of common genetic variants with the disease phenotype. In many disorders with a previously unknown genetic architecture, GWASs proved crucial to gain first insights into the underlying biological pathways, given that it allowed for an unbiased, hypothesis-free screen for risk factors on a genome-wide basis.\(^{36}\) Common variants are investigated in GWASs and are frequent in both cases and controls, usually conferring a relatively small risk, which is often insufficient to explain much of the overall disease risk and hence inadequate for genetic counseling purposes. For many neurodevelopmental disorders, however, the success of GWAS came relatively late, as unexpectedly large sample sizes were needed. For GGE, the first sufficiently powered GWAS was the seminal study for the European EPICURE consortium, which discovered common variants at \(CHRM3\) at 1q43, \(VRK2/FANCL\) at 2p16.1, \(ZEB2\) at 2q22.3, \(PNPO\) at 17q21.32, and \(SCN1A\) at 2q24.3 as risk factors for GGE.\(^{37}\) This discovery required the joint power of more than 3,000 patients and 3,000 controls. A follow-up meta-analysis reinforced the association with \(VRK2/FANCL\) at 2p16.1, while calling the other association signals into question.\(^{38}\) In addition, the meta-analysis performed by the ILAE Consortium on Complex Epilepsies also emphasized the association with common \(SCN1A\) variants with all epilepsy subtypes combined that were joined in this analysis. These results suggest that genetic risk factors at previously unknown loci might give novel insight into GGE pathophysiology and that \(SCN1A\) variants confer risk along a spectrum of variants, ranging from the de novo dominant mutations in Dravet syndrome to the common variants predisposing to common epilepsies. It should be noted, however, that it is inherent in the technology of GWASs that the causative variant in this region cannot be pinned down through genetic studies. In fact, the variant with the strongest association signal is not within the \(SCN1A\) gene, but between the various genes of the sodium channel gene cluster on chromosome 2.\(^{38}\) Regardless of these findings, the contribution of common variations in GGE seems too limited to a few prominent loci that confer relatively little risk.

**Next-Generation Sequencing**

With the limited availability of monogenic families and having exhausted the genetic potential of genome-wide studies of copy numbers and common variants, the field is currently turning to the emerging technologies of exome sequencing and genome sequencing to search for additional genetic risk factors in common genetic epilepsies. Although the field of gene identification in severe epileptic encephalopathies is currently on the upswing due to the increasing discovery of de novo mutations, this genetic paradigm is usually not invoked in patients with mild epilepsies. This is because the de novo events, frequently considered in severe disorders that limit an affected individual’s capacity to reproduce, are unlikely to be found in common disorders. Accordingly, GGE genetics is largely limited to association studies, which present a perceptible challenge with next-generation sequencing technologies.

The first results from exome sequencing in GGEs were largely negative. An association study on rare variants identified through exome sequencing in GGE that were followed up in more than 800 GGE patients and 1,830 controls found no “Goldilocks variants”—rare, but still relatively frequent genetic variants that predispose to GGE.\(^{39}\) However, larger-scale studies probing the genetic architecture of GGE are currently underway, hopefully giving insight into the underlying biology through larger sample sizes.

**An Integrative View of GGE Genetics**

Despite the deeply convincing evidence for a genetic contribution in GGE through twin and family studies, the genetic architecture underlying these common epilepsies remains to be solved. In fact, as of 2015, gene discovery in GGE has even fallen behind the speed of gene identification in other epilepsies, demonstrating the complexity in pinning down heterogeneous rare risk factors, which—by exclusion—are believed to harbor most of the genetic risk. The decade-long search for genetic risk factors for GGE has resulted in several unexpected findings along the way, including the discovery of potentially treatable GLUT1-deficiency syndromes in atypical cases and the genetic overlap with other neurodevelopmental disorders through the identification of CNVs (\(\sim\)Table 1). Genome-wide association studies have highlighted common genetic risk factors: The association of variants close to \(SCN1A\) has emerged as a common theme in various epilepsies. Although these studies have successively chipped away at the genetic architecture of GGE, the bulk of the genetic risk remains unexplained. Large-scale exome or genome-sequencing studies will probably substantially fill this gap in the near future.

**References**

Mullen SA, Marini C, Suls A, et al. Glucose transporter 1 de
Chen Y, Lu J, Pan H, et al. Association between genetic variation of
Cherepanova NS, Leslie E, Ferguson PJ, Bamshad MJ, Bassuk AG.
Subaran RL, Conte JM, Stewart WC, Greenberg DA. Pathogenic
Suzuki T, Delgado-Escueta AV, Aguan K, et al. Mutations in EFHC1
Berkovic SF, Mulley JC, Scheffer IE, Petroiu S. Human epilepsies:
Schubert J, Siekierska A, Langlois M, et al; EuroEPINOMICS RES
Harkin LA, Bowser DN, Dibbens LM, et al. Truncation of the GABA
Wallace RH, Wang DW, Singh R, et al. Febrile seizures and
care of familial idiopathic generalized epilepsy. Nat Genet 2012;
Mefford HC, Eichler EE. Duplication hotspots, rare genomic dis-
Sharp AJ. Emerging themes and new challenges in defining the role of structural variation in human disease. Hum Mutat 2009;
Subaran RL, Conte JM, Stewart WC, Greenberg DA. Pathogenic EFHC1 mutations are tolerated in healthy individuals dependent on reported ancestry. Epilepsia 2015;56(2):188–194
Helbig I, Lowenstein DH. Genetics of the epilepsies: where are we and where are we going? Curr Opin Neurol 2013;26(2):179–185